Table 2Cyclobenzaprine compared with amitriptyline (Carette 1994)

Domains pertaining to strength of evidenceMagnitude of effectStrength of evidence
Number of studies; number of subjectsRisk of bias (design/quality)ConsistencyDirectnessPrecisionSummary effect size (95% confidence interval)High, Moderate, Low, Insufficient
50% response
No dataNANANANANAInsufficient
Fibromyalgia Impact Questionnaire: Mean change
No dataNANANANANAInsufficient
Pain: Mean change in visual analogue scale
1; N=184RCT/FairNADirectImpreciseNSD, P value NRLow
Fatigue: Mean change in visual analogue scale
1; N=184RCT/FairNADirectImpreciseNSD, P value NRLow
Overall adverse events
1; N=184RCT/FairNADirectPreciseRR 1.02 (0.96 to 1.11)Moderate
Withdrawals due to adverse events
1; N=184RCT/FairNADirectImpreciseRR 1.90 (0.82 to 4.44)Low

From: Appendix F, Strength of evidence

Cover of Drug Class Review: Drugs for Fibromyalgia
Drug Class Review: Drugs for Fibromyalgia: Final Original Report [Internet].
Smith B, Peterson K, Fu R, et al.
Portland (OR): Oregon Health & Science University; 2011 Apr.
Copyright © 2011, Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.